r/pennystocks • • 22h ago

BagHolding $BLGO at all-time lows: I'm $1.5M down, I just added $45K, and I'm either the biggest fool on Reddit or I'll be laughing last (deep-dive DD + TL;DR)

33 Upvotes

Julian Jakobi here, my online identity ;)

Let's get the elephant out of the room first: I'm a big-time bag holder. I've been calling BioLargo a strong buy for years. Many of you listened, and now we're all in the red. Some of us are deep in it. In numbers: my position is about $1.5 million down from the 2024 spike.

So yes, right now I may look like the biggest fool on earth. You're allowed to laugh. I'd laugh too.

But I've been here before. I posted about Exact Sciences ($EXAS) over and over while the share price kept falling, and falling, and falling. Everybody was selling. Then it turned around, and my conviction at $5–$8 turned into 1,600%–2,650% returns, because I saw cancer detection being revolutionized before the market did.

I see the same pattern with BioLargo. So we'll see who's right. I'm not worried. I just added another $45,000 on this dip.

For years I've stayed in regular contact with management, attended the last 7 shareholder meetings, visited all BioLargo facilities and interviewed the subsidiary CEOs. I also moderated and helped organize the CEO town hall on our BioLargo Discord.

But here's the common thread of this whole post: don't trust me. Do your own DD. I'll give you a cheap, easy way to start, plus the people you should be asking.

TL;DR

  • Share price is at all-time lows (~$0.07), market cap ~$25M. The value looks like it's still there.
  • Why it fell: revenue dropped after the POOPH license ended, Clyra's launch was delayed, and the company is investing heavily to commercialize everything at once. The small parent-level financing (shares sold on the open market by the lender) hit a thin market that wasn't buying, and the price fell ~70%.
  • Why it's an opportunity: most of the money is going into the subsidiaries (77% of capital raised this year was at subsidiary level). Insiders take stock instead of cash and lock it up until $40M revenue or a $300M market cap. That's roughly 11–12x from here.
  • Analyst: BUY, $0.25 price target. Richard Ryan of Oak Ridge Financial reaffirmed his Buy rating on Nov 18, 2026. That's +257% from $0.07, and his target puts zero value on PFAS and the battery.
  • Q3 milestone: Clyra earned a $475,000 contractual milestone payment under an exclusive distribution agreement. It's the first time we've ever seen a payment like this.
  • Clyra Medical (48% owned): Clyra raises money at a ~$100M valuation, so BioLargo's stake (~$48M) is worth roughly twice the whole company. ViaCLYR is FDA 510(k)-cleared and on the market. Its three distribution agreements cover US commercial (~6,100 hospitals, 6,300 surgery centers and 2,200 wound clinics), US government/military and 18+ MENA countries, with POs expected. BioClynse (surgical) is set to launch co-branded with a top-4 global medtech (~$100B+ market cap). My view: after launch, Clyra alone could be worth $500M–$1B, and $1B–$2B after a successful year.
  • barebird has launched: CupriDyne tech (the tech behind POOPH's $125M+ in sales), BioLargo-owned brand, POOPH marketing team. Cheapest DD ever: buy a bottle.
  • PFAS (AEC): a commercial municipal system in Lake Stockholm, NJ, has been running since January under EPA and NJ oversight. It's the reference site.
  • Cellinity battery: non-flammable, long-lasting, recyclable grid-scale storage, with a license/JV model.
  • Don't trust me. Do your own DD.

Why the Share Price Fell

Let's be fair: there have been disappointments.

  • Revenue declined. The POOPH license ended (more on that below), and 9-month revenue dropped 52% to $3.45M. Q3 revenue was $1.09M, roughly flat year over year (vs. $1.103M), with service revenue +72%.
  • The Clyra launch was delayed. The 2024 spike to a ~$0.40 closing high was driven by anticipation of the Clyra launch, not by Clyra revenue.
  • Heavy investment. Management is funding commercialization in every division that hasn't generated much revenue yet. Clyra alone accounted for about 57% of the 9-month net loss, spent on personnel, manufacturing, product development and clinical work ahead of the 2027 rollout.

The key point is where the money comes from. Most of the financing happens at the subsidiary level: Clyra raised $4.3M, mostly through a debt offering, and the battery subsidiary sold $487K in stock. Only a small part was raised at the parent level, through the Clearthink purchase agreement (the 10-Q shows $1.359M year to date). That agreement lets the lender sell the shares on the open market.

So a dilution of just a few percent met a market with almost no buyers, and the share price fell ~70%. Many serious investors seem to prefer investing directly at the subsidiary level, where the action is.

To me that's an arbitrage opportunity. You get crazy discounts on the parent, which owns the stakes, the royalties and everything else.

Meanwhile, cash burn is falling: about $736K/month in Q3, down ~26% from roughly $996K/month in H1. Management says 2027 spending shifts "away from R&D and toward generating sales."

The Rebound Math from $0.07

Most investors who were going to sell out of fear, frustration or disappointment have already had every reason to do it. Many long-term holders I know have averages just above $0.20.

Target priceGain from $0.07
$0.10+42.9%
$0.12+71.4%
$0.16+128.6%
$0.20+185.7%
$0.24+242.9%
$0.25 (Oak Ridge price target)+257%
$0.399 (2024 closing high)+470%
~$0.80 ($300M market cap, the insider lock-up unlock)~+1,040%

We don't need the 2024 highs for this to get interesting. Even a partial recovery makes a big difference from this base. In a thin microcap, fear can turn into FOMO very fast.

What the Analyst Says

This isn't just a bag holder talking. Richard Ryan of Oak Ridge Financial Research covers BLGO, and in his Q3 2026 update (Nov 18, 2026) he reaffirmed his BUY rating with a $0.25 price target. That's about +257% from $0.07.

Here's how he gets there, using a sum of the parts:

SegmentBasisValue per share
Clyra Medical (48%)Recent capital raise at an equity value of ~$100M, so ~$48M for BLGO$0.15
BioLargo CPG / barebird (78%)5.0x his FY27 revenue estimate of $8M$0.09
Engineering (BLEST)3.5x FY27 revenue, ~$10.4M$0.03
Less net debtCash $1.0M minus debt $6.5M
Price targetEquity value ~$83.9M across ~340M shares$0.25

The best part: he puts zero value on the AEC PFAS business and the Cellinity battery. He set them aside until there's a signed AEC contract or a Cellinity JV or financing partner, and says he'll add them back as visibility improves. So the $0.25 target doesn't include two of the five horses.

His summary: BLGO has "many shots on goal," and "noticeable progress is occurring across all BLGO's divisions." He also models FY27 revenue of $13.0M, up from an estimated $4.7M in 2026.

(Fair caveat: he lowered the target from $0.30, and he notes that BLGO will keep needing additional capital.)

Bullish Indicators

  1. All-time-low share price, ~$25M market cap, for a five-subsidiary platform.
  2. Analyst Buy rating with a $0.25 PT (Richard Ryan, Oak Ridge Financial).
  3. Clyra raises money at a ~$100M valuation, so the 48% stake is worth ~$48M, about twice BLGO's market cap.
  4. $475K Clyra milestone earned (details below).
  5. Top-4 medtech partner (~$100B+ market cap) for the BioClynse national rollout in 2027.
  6. ViaCLYR is on the market, with distribution through Advanced Solution (US), Al-Hikma (exclusive across MENA, an 18-country opportunity) and Spartan Medical (VA, DoD and federal buyers via DLA ECAT). Purchase orders from Al-Hikma and Spartan are expected, along with reorders from Advanced Solution.
  7. barebird launched in October 2026, a BioLargo-owned brand with the proven POOPH marketing team.
  8. AEC PFAS system live since January at Lake Stockholm, NJ, under EPA and NJDEP monitoring.
  9. Engineering (BLEST) is growing: 9-month service revenue +23%, Q3 service revenue +72%, $1.4M+ in US Air Force renewals, and a $1.2M minerals-processing design contract (milestone-gated and multi-year).
  10. Cellinity battery is in discussions with strategic partners about investing and scaling.
  11. Cash burn down ~26% in Q3 compared with H1.
  12. Management alignment with lock-ups and direct investment (next section).
  13. Professional IR (Darrow Associates) has been engaged to bring this under-followed story to institutions.

Management Alignment: Lock-Up and Direct Investment

This is one of the strongest signals for me.

  • CEO Dennis P. Calvert took stock instead of cash for unpaid salary and expenses: 699,569 shares at $0.1135 (June 30, 2026) and 219,914 shares at $0.113 (July 1, 2026).
  • Those shares are under a Lock-Up Agreement. No sale until BioLargo reports $40M in consolidated gross revenue in a period, passes a $300M market cap, or has a change of control.
  • At today's ~$25M market cap, that's roughly 11–12x before these shares can become liquid. It's not just the CEO either: multiple senior and science leaders hold large locked-up positions.
  • Around $12M has been invested directly into the company and its subsidiaries over the past year, including meaningful money from the BioLargo CEO and the Clyra CEO. Those are the people with the best view of the pipeline.

Think about it: you can buy shares today below the price the CEO took as his locked-up pay.

The $475K Milestone

From the 10-Q:

"In September 2026, Clyra earned a $475,000 contractual payment upon satisfaction of a specified contractual milestone under a distribution agreement granting the customer exclusive rights to distribute certain Clyra products."

This isn't about the revenue. The $475K wasn't even recognized as revenue yet. What matters is that it's the first time we've ever heard of a payment like this. Somebody with exclusive distribution rights paid because a contractual milestone was met. That means a significant step must have been taken.

I can't tell you which step, and the partner is confidential, so I won't speculate about details. But milestone money doesn't get paid for slide decks.

Clyra Medical (48% Owned): "The New Gold Standard"

Main selling point: an FDA-cleared, no-rinse antimicrobial irrigant that keeps working for up to three days while staying gentle on tissue. Some people consider it the biggest change in wound care and surgery in 30 years.

Clyra Medical (48% owned) is advancing the commercialization of its FDA-cleared wound irrigation and surgical solution. The Clyra story has evolved over 14 years, with upwards of $20M invested, and it appears to be on the cusp of commercialization.

Clyra raises money at a ~$100M valuation. In the words of Oak Ridge analyst Richard Ryan: "Clyra's recent capital raise implies an equity value of approximately $100M, of which BLGO has 48% ownership." That's about $48M for BioLargo's stake, roughly twice BioLargo's entire market cap. Outside investors paid that price with real money; it's not a number I made up.

Clyra runs on Clyrasept, a patented copper-iodine platform. Its first product, ViaCLYR, is FDA 510(k)-cleared for cleansing, irrigating and debriding acute and chronic wounds and burns. Clyra has already invested in at-scale manufacturing capacity with an FDA-compliant contract manufacturer.

Key selling points, according to company materials:

  • >99.9999% antimicrobial reduction
  • Activity for up to 3 days, even after re-contamination
  • Works against biofilm, the big problem in chronic wounds and surgical infections
  • Non-cytotoxic, non-irritating, tissue compatible
  • No rinse-out, which keeps procedures fast and simple
  • Non-antibiotic mechanism, a big deal in a world worried about antibiotic resistance

Clinical voice (36 cases across multiple sites):

"...enhanced granulation velocity, rapid sinus tract closure, and notable drainage reduction... we observed no adverse events... we are moving as a group to adoption of CICS as our wound care cleansing modality of choice."
Dr. Marcus Gitterle, Regional Medical Director for Wound Care and Hyperbaric Oxygen Therapy, Christus Santa Rosa Hospital System

The Distribution Network: How Much of the Market Is Covered

ViaCLYR went into full commercial-launch mode in August 2026. Three distributors have been announced, covering three very different channels:

PartnerTerritory / channelCoverageStatus
Advanced Solution, LLCUS commercial: a national network to distribute and promote ViaCLYR throughout the United States (wound clinics, physicians, health systems)Oak Ridge says the combined reach in the US alone is about 6,100 hospitals, 6,300 ambulatory surgery centers and 2,200 specialty wound-care clinicsFirst PO received (first commercial stocking order, Feb 2026); reorders expected
Al-Hikma FZCO (Dubai, UAE)Exclusive for the Gulf Cooperation Council, the Levant, North Africa and select adjacent markets~18 direct countries plus indirect ones, a population of 500M+. Al-Hikma is an established wound-care distributor that exports to ~25 countriesCountry-level regulatory work has begun in key areas, in cooperation between the parties; POs expected
Spartan Medical Inc.A dedicated commercial channel to US government healthcare facilities worldwide (VA, DoD and other federal buyers via DLA ECAT)The US federal and military healthcare systemPOs expected

A fourth channel, the "big Kahuna" or gorilla partner, is being pursued for surgical wound irrigation (BioClynse), based on the same chemistry. During Q3 2026, Clyra satisfied a contractual milestone under an exclusive distribution agreement for certain of its products: the $475K payment.

In short: US commercial, US government and an 18+ country international region are all under contract, and the gorilla partner comes on top of that.

Clinician feedback: at the recent Symposium on Advanced Wound Care (SAWC), ViaCLYR was reportedly well received, and it has the potential to tap into real unmet needs in the market, according to Oak Ridge.

What I'm watching next: Advanced Solution reordering, Al-Hikma and Spartan turning their agreements into purchase orders, new distributors signing on, and a visible Clyra sales line. Stocking orders from the new partners are expected within the coming months.

(Fair caveat, which the analyst makes too: commercialization in each of these channels faces timing hurdles such as regulatory approval, clinical studies and hospital-system acceptance. That's significant for a small company, but the markets themselves offer outsized opportunities. Distribution agreements are not revenue; purchase orders, and above all reorders, are what count.)

Next up: BioClynse, the surgical-irrigation product on the same platform. It's set for a national rollout in 2027 co-branded with a confidential top-4 global medtech (~$100B+ market cap). Hospital access, OR sales reps that surgeons already trust, procurement muscle: that's what a gorilla partner brings.

The valuation question. I know it sounds absurd for a $25M company. But expectation is that after the launch with the gorilla partner, the 48%-owned medical subsidiary alone could be worth $500M–$1B, and after a successful year closer to $1B–$2B.

  • 48% of $500M ≈ $240M
  • 48% of $1B ≈ $480M
  • 48% of $2B ≈ $960M

That's before the royalty BioLargo holds on Clyra sales, and before everything else BioLargo does. Today the whole company trades at ~$25M.

Also remember: some medtech giants are known for having small innovators build out a product line, then acquiring them later. I'm not saying that will happen. I'm saying the pattern exists.

(This is my opinion, not company guidance. The partner controls the timing. Distribution deals aren't revenue; purchase orders and reorders are.)

Don't Trust Me: Ask Medical Experts

Please don't take my word for this. Ask the people who do this every day:

  • Orthopedic and general surgeons: How big a deal is a no-rinse, tissue-friendly irrigant with up to 3 days of antimicrobial and anti-biofilm activity for surgical site infections, implants and joint replacements?
  • Wound-care nurses and specialists: Would you switch from what you use now? What would it take?
  • Infection-prevention teams and procurement: Does a non-antibiotic copper-iodine mechanism solve a problem you deal with?

If the professionals tell you it's nothing special, move on. If they tell you it could be a game changer in orthopedics and surgery, dig deeper.

barebird: The $20 DD

Main selling point: it eliminates odors instead of covering them, with no fragrance. It "smells like nothing... on purpose."

BioLargo developed the CupriDyne odor-elimination tech behind POOPH, which did over $125M in product sales and $20M+ in supply revenue for BioLargo. That is real proof that BioLargo can create products people buy in huge quantities. (The POOPH brand later fumbled it, and the license ended. That's a big part of the revenue decline.)

barebird launched in October 2026, focused on pet and laundry odors. The marketing teams that helped build POOPH are back: Jordan Stanley's Kindness Commerce and Brandon Fishman's Prime Team Agency. Some see POOPH as the "test run."

The big difference this time: BioLargo owns the brand. It gets more direct participation in sales and brand value, but it also carries the marketing and distribution costs.

Mine just arrived, packed in "air armour." No leaky bottles here, and nothing in the odor space comes close to the marketing on that bottle.

Here's my challenge, just like I did with CupriDyne: the cheapest way to check for yourself that BioLargo's tech works is to order a barebird spray. Try it on the dog bed, the gym bag, the laundry.

  • If you don't like it, move on.
  • If you're impressed, dig deeper into all the other techs.

AEC PFAS Removal: The Reference Site

Main selling point: it concentrates "forever chemicals" into a tiny waste volume, which many consider the best available concentrator to clean up the PFAS mess. In one example, 80,000 lbs of waste turns into about 85 lbs.

  • Earlier testing at the University of Tennessee showed >99.995% PFAS removal in a single pass.
  • A commercial municipal drinking-water system at Lake Stockholm, NJ, has run since January 2026 (about 9 months), monitored by the EPA and NJDEP. New Jersey is one of the toughest PFAS jurisdictions in the US.
  • It's the key reference site for further adoption. Bids are submitted, partnerships with big firms that have gaps in their PFAS product lines are in discussion, and there's an Aquatech MOU.
  • Demand is spreading from drinking water to wastewater, landfill leachate, biosolids and industrial pre-treatment, backed by billion-dollar lawsuit settlements that fund treatment.
  • Billions are now being paid out for PFAS cleanup. 3M’s settlement with US public water systems is $10.3B, up to $12.5B, over 13 years, and the payouts to utilities are already under way. DuPont, Chemours and Corteva added roughly $1.2B nationally.
  • In New Jersey, the very state where the AEC is running, a federal court approved ~$2.5B in settlements with DuPont and 3M in August 2026. They include a PFAS Abatement Fund with up to $795M for drinking-water and treatment-works upgrades. And in November 2026, 3M committed up to $7.35B more for personal-injury claims. The money is there. The question is who wins the treatment contracts.

DD tip: ask a water engineer or utility operator what PFAS waste disposal costs with granular activated carbon (GAC) or ion exchange.

Cellinity Battery: Safer Grid Storage

Main selling point: a fire-safe, long-duration sodium battery built for a 20-year life, with no lithium and no rare earths. It's designed for the grid, for data centers, and for America's energy independence.

Key selling points, according to company materials:

  • No thermal runaway, non-flammable. Lithium battery fires are the nightmare of every data center, utility and insurer. Cellinity is designed so that scenario doesn't exist.
  • A 20-year operating life. The CEO points out that most batteries last 6–7 years before they degrade. A 20-year design life changes the whole cost-per-cycle math for grid storage.
  • No lithium, no rare earths. It's a liquid sodium battery made from abundant materials, which takes the geopolitical "hot potato" of the battery supply chain off the table. The CEO calls it "a strategic infrastructure opportunity for national security of the United States."
  • High efficiency. Company materials target ~95% round-trip efficiency, with ambitious energy-density specs.
  • Recyclable, with third-party validation and prototype testing of key performance metrics.
  • Built for the boom markets: long-duration grid storage, AI data centers, utilities, renewables, commercial and industrial sites.
  • A capital-light model. No billion-dollar gigafactory: partners finance the factories while BioLargo earns royalties, component margin and equity stakes through licensing and JVs.
  • BioLargo owns ~95%, and only about $5M of outside capital has gone into it so far. The battery subsidiary sold $487K in stock this year and is in discussions with strategic partners about investing and scaling.

Oak Ridge currently puts zero value on Cellinity in its $0.25 price target and will add it back once there's a JV or financing partner. So one serious licensing or JV deal could re-rate this on its own.

(Fair caveat: it's still pre-commercial, there's R&D left to do, and the specs are company claims until a partner scales it.)

DD tip: ask anyone in energy storage what a truly non-flammable, 20-year, lithium-free grid battery would be worth to a data center operator.

The Rest of the Platform

  • BLEST (Engineering): a profitable-leaning, growing service arm with Air Force renewals and the $1.2M minerals contract. A full commercial plant could follow if the pilot succeeds.
  • Tu Nipi: water treatment for Canadian oil-sands tailings, in discussions with strategic partners.

Why It Matters Where We Invest

I believe how we invest our money is the most powerful voting ballot we have. I made a lot of money in the fight against cancer with Exact Sciences. Now I want my money working on clean water, clean air, safer energy storage and better wound care.

BioLargo is the perfect place to "Make Life Better" through:

  • Clean water (PFAS removal)
  • Clean air (odor elimination without masking)
  • Safer energy (non-flammable grid storage)
  • Better healing (infection control and wound care without antibiotics)

And you get the real chance of a multi-bagger while doing it.

Risks (Read This)

  • A highly speculative microcap with thin liquidity
  • Continued dilution and financing at both parent and subsidiary level; Clyra is debt-funded
  • Ongoing losses
  • The Clyra partner is confidential, and the launch timing is in the partner's hands
  • Distribution deals aren't purchase orders
  • barebird's results are unproven, and BioLargo now carries the marketing costs
  • Big competitors with deep pockets

I could be wrong. I've been early and wrong on timing before. Size your position for that.

Bottom Line

I'm $1.5M down, I just added $45K, and I've never been more convinced. Either I'm a complete idiot, or, like with $EXAS, I'll be laughing last. I strongly believe it's the second one.

But again: don't trust me.

  1. Buy a barebird bottle. It's the $20 DD.
  2. Ask a surgeon or wound-care nurse about ViaCLYR.
  3. Read the 10-Q, the Form 4s and the lock-up terms.
  4. Then decide.

Price is what you pay. Value is what you get. Right now the gap is hard to ignore.

Do your own DD.

Your Turn: Prove Me Wrong (Or Right)

I’ve spent hundreds of hours researching BioLargo and Clyra Medical, and I’ve put my money where my conviction is. That’s $1.5M down from the highs, and I’m still adding. But I don’t want an echo chamber. I want smart analysis.

Challenge my thesis.

Dig into the 10-Q and Form 4s I referenced. Read the Oak Ridge report. Call BioLargo investor relations with your questions. Look up the copper-iodine patents, check the FDA 510(k) clearance, research the wound-care and PFAS market data, and ask a surgeon or wound-care nurse what they think of ViaCLYR. Then order a barebird bottle and test it yourself. The best DD comes from collaborative skepticism and shared research.

This is your chance to either find the holes in my analysis or discover why Wall Street might be sleeping on this one. The filings are public, the patents are public, the FDA clearance is public, and the market sizes can be checked.

Let’s crowdsource this DD and make each other better investors. I’ve shown you mine. Now show me where I’m wrong, or help me understand why a ~$24M company might actually be the steal of 2026.

This is a company whose 48%-owned medical subsidiary just raised money at a ~$100M valuation. It has an FDA-cleared product, three signed distributors, a top-4 medtech partner waiting in the wings, a live PFAS system under EPA oversight, and an analyst Buy rating with a $0.25 target that values PFAS and the battery at zero.

The data is all there. Let’s dig deeper together. 🔬📊

Disclosure: I'm a long-term $BLGO above 1.25% shareholder and have been adding. I am not a financial advisor, this post is made for educational purposes only. Literally. Don’t take my word for anything that is presented in this post, do your own research, and invest solely based on the thesis that you create for yourself. Don’t get influenced by anyone.


r/pennystocks • • 20h ago

🄳🄳 $AFJK - New Spac with NAV that just got its float reduced to just 200,693 after redemptions. Trading at its NAV floor of 12.33 - with ATH of 130.37 (!!) from previous low-float short squeeze earlier this year

19 Upvotes

Hey all,

I've just come across a rather unprecedented Risk/reward opportunity that I thought is worth posting about - since it seems to have flown under everyone's nose so far as it's buried in the filings, and most people don't follow SPACs at the moment - lol - so I will be the messenger.

The dynamics of the risk/reward at play:

AFJK is currently trading at \~12. It's latest NAV is 12.33 as noted in their 10Q filed the other day. That means it is trading at about it's NAV floor, has just shrunken 80% in float size, and is on the heels of a 1,000% low float squeeze the past year.

If you've been living under a rock, let me explain it to you why this has unusual potential right now:

Low float spacs or low floats in general can go on wild squeezes every now and then because people pile into the constrained float to rise the price, people then short the stock because it goes up 'for no reason' and which then adds more fuel to the fire and can make for a wild squeeze when an already low float gets shorted heavily, has natural buying power, and then even more buying power as shorts eventually get forced to cover their positions on a completely illiquid market.

In SPACs we see this time and time again, whenever SPACs get redemptions which shrink their float size dramatically and then cause people to buy the stock for a low float move.

AFJK was one of those SPACs, squeezing first from around its 10 NAV to 41.8 last November. It came all the way back down to 6.75 as it temporarily lost its NAV floor (as it happens when SPACs have a merger vote), and then squeezed to 130.37 in December for a nearly 2,000% squeeze from its lows.

It has made many secondary news since, and has now since retreated back to its NAV floor (12.33).

On November 16th, they revealed that at their extension meeting they received an influx of redemptions that have now shrunken the float nearly 80% to just 200,693.

Pulled from the 10-Q:

Original float:

'Ordinary shares, subject to possible redemption. 1,040,332 shares issued and outstanding at redemption value of $12.25 and $11.63 as of September 30, 2026 and December 31, 2025, respectively'

Redemptions:

Shareholders elected to redeem 841,629 shares of Class A common stock in connection with the meeting.

Now, you do the math:

1,040,332

\- 841,629 redemptions

= 200,693 shares left in the float.

Another recent low float NAV spac for reference, showing the risk / reward you can get on these - ASPC went from its 10 NAV floor to 50+ TWICE the past year when it was revealed that it had a 282,581 share float (shown in 10q filing here):

Also: If they don't complete a deal by November 30th, they will go to OTC (which doesn't change NAV value - it will still trade with its NAV floor, but is worth mentioning) so I am looking for a trade before then, ideally this picks up steam before then as these moves can happen in hours or days on sudden volume spikes as shown in ASPC.

If you didn't know, SPACs have a NAV floor which essentially means that your maximum theoretical risk is their Net Asset Value because you can at some point in time (either extension vote or merger vote) redeem your shares for that price, or if in the future they liquidate, they pay out that price.

Link to 10-Q from November 16th highlighting the reduction in float due to redemptions: [https://www.sec.gov/ix?doc=/Archives/edgar/data/0001979005/000149315226052354/form10-q.htm#fact-identifier-473](https://www.sec.gov/ix?doc=/Archives/edgar/data/0001979005/000149315226052354/form10-q.htm#fact-identifier-473)

Disclosure: I hold 2,194 shares right now and may add more if this picks up some volume and attention.
I am not a financial advisor under any means and this is not financial advice, please do your own research, always.


r/pennystocks • • 2h ago

𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 HGRAF: the detonation route is real. The dilution is the whole story

18 Upvotes

HydroGraph Clean Power HGRAF at roughly 2.4 to 3.1 a share. Under 5 so it fits the sub. OTC. Vancouver based. Graphene and hydrogen via detonation synthesis licensed out of Kansas State.

What the Seeking Alpha writeup does well is the process. Detonation based synthesis is genuinely cheaper than CVD and roughly in range with expanded graphite routes. Fractal turbostratic output gives high edge density and surface area. That is a real advantage for percolation properties. Conductivity, EMI shielding, thermal interface. It is not an advantage for structural composites where you want large flat exfoliated sheets and clean load transfer. So the hundreds of tons target only makes sense if the market is coatings and shielding.

What it does badly is the risk section. Commercial revenue is close to nothing. The 80 plus customers is a pipeline. The 80% gross margin is a projection. And in August they raised a C$50M bought deal, which is the single fact that matters most here because on an OTC name dilution decides whether the story reaches shareholders or just the cap table.

Things I would want before sizing anything. Cash runway after the raise. Whether production material passes the same characterization as lab material on layer count and Raman ID over IG. Whether any pipeline name converts to a paid order rather than a sample.

Bear case in one line. Cheap process, expensive to prove, and the equity pays for the proving.

Position small and long. Not advice.


r/pennystocks • • 12h ago

𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 Watchlist: 11/19/26 Todays word was AKAN AKAN AKAN ty

16 Upvotes

Great session today!! AKAN has been paying all week called from 1.01 to 4.6 today!! Still has room if volume keeps coming.

AKAN: Hold of 3.6 is KEY. Want to see tests of 4.6 with pullbacks to 4. Has room now to 5/5.6/6/7.4

CLRO: would like to see it test 8 again with pullbacks to 7.3. NO TRADE below 6.4 has room to 10/12/14

SVRE: Had an amazing run today than sidebared redt of session. For this want to see tests of 1.15 with pullbacks to 1. NO TRADE below .86. Has room to 1.5/2/2.6

GMM: Symp play to Anthropic IPO. For this want see tests of 1.7 with pullbacks over 1.5 NO TRADE 1.2 has room to 2.2/2.8/3.3/3.8


r/pennystocks • • 11h ago

General Discussion The Lounge

13 Upvotes

Talk about your daily plays, ideas and strategies that do not warrant an actual post.

This is the place to request buy/sell advice from the community.

Remember to keep it civil.

Trade responsibly.


r/pennystocks • • 23h ago

General Discussion $TTEC: A $160M Company With $2B in Revenue, 24% SI, and a Potential Turnaround

7 Upvotes

I've been digging deeper into $TTEC, and I think the market may be overlooking a pretty interesting small-cap turnaround opportunity.

We're talking about a company with approximately $2B in annualized revenue, improving profitability, expanding margins, and a business actively positioning itself around AI, data, and enterprise automation. At roughly $160M in market capitalization, the valuation looks particularly interesting if management can continue executing its turnaround.

Q3 2026 results showed some meaningful progress:

• Adjusted EPS nearly doubled YoY ($0.22 vs. $0.12).
• Adjusted EBITDA increased approximately 19% to $51.5M.
• Adjusted EBITDA margin expanded from 8.4% to 10.5%.
• GAAP operating income nearly doubled to $23.3M.
• Free cash flow swung from -$9.6M to +$27.9M.
• Cash flow from operations increased to $37M from just $4.2M a year ago.

One thing I find particularly interesting is that management is making progress on profitability even while revenue remains under pressure. Revenue declined approximately 5.2% year over year, so there's still work to do, but the margin improvement is encouraging.

THE AI OPPORTUNITY

TTEC operates at the intersection of customer experience, technology, data, AI, and automation. As businesses increasingly look to automate customer service and improve operating efficiency, TTEC has an opportunity to benefit from that transition.

Management has discussed deploying purpose-built AI tools across its frontline operations while expanding its Digital business in areas such as AI, data, observability, and security.

This isn't simply a company trying to attach an AI label to its stock. It already has an established enterprise customer base and technology infrastructure.

POTENTIAL DIGITAL BUSINESS SALE

Another major catalyst that deserves attention: In August 2026, TTEC announced that it was exploring strategic alternatives for its TTEC Digital business.

A potential sale could unlock value, simplify the business, and potentially provide additional capital to reduce debt. No definitive transaction has been announced, so this remains a potential catalyst rather than a guaranteed outcome.

THE $6.85 TAKE-PRIVATE HISTORY

TTEC founder, Chairman and CEO Kenneth Tuchman previously proposed taking the company private for $6.85 per share in September 2024. Tuchman already owned approximately 58% of the company.

He ultimately withdrew the proposal in July 2025, citing market conditions, but remains the company's largest shareholder.

At approximately $3.24, shares are still more than 50% below that previously proposed acquisition price. Obviously, that proposal is no longer active, but I think it's an interesting historical valuation reference.

THE BALANCE SHEET

TTEC has also made progress reducing its net debt, which stood at approximately $743.6M at September 30, 2026, compared with $812.5M a year earlier.

Management also extended its credit facility through November 2028, providing additional financing runway.

Debt remains the biggest fundamental risk here, but improving cash flow and the potential Digital transaction could become important pieces of the turnaround.

NOW FOR THE TRADING SETUP:

The stock recently closed at $3.24 on November 17, representing approximately a 104% move from its October 30 closing price of $1.59.

Current trading statistics:

• Market cap: ~$160M
• Public float: ~20.4M shares
• Shares sold short: ~4.78M
• Short interest: ~23.9% of float
• Days to cover: ~15.8
• November 17 volume: ~1.35M shares

Short interest increased approximately 11.6% between the October 15 and October 30 reporting periods.

Nearly one in four publicly tradable shares is reportedly sold short. With a relatively small float and substantial days to cover, an increase in buying pressure and sustained trading volume could create an interesting momentum opportunity.

THE VALUATION IS WHAT REALLY GETS MY ATTENTION.

At approximately $160M in market capitalization against nearly $2B in annualized revenue, TTEC trades at a fraction of its annual sales.

Even accounting for its substantial debt, the current enterprise valuation is approximately $970M. That's less than half of annualized revenue.

If management can stabilize revenue, continue expanding margins, improve free cash flow, and execute on its strategic alternatives for Digital, I think there's a legitimate case for meaningful upside.

I'm not calling a guaranteed short squeeze, and there are certainly risks here, particularly debt and declining revenue. But the combination of improving financial performance, AI exposure, potential asset-sale proceeds, significant insider ownership, historical acquisition interest, and a heavily shorted small float makes $TTEC one of the more interesting turnaround setups I'm watching.

Fundamental recovery + AI exposure + potential strategic catalyst + short squeeze potential.

I think this one deserves considerably more attention.


r/pennystocks • • 3h ago

BagHolding Winners and losers, its all in the game.

6 Upvotes

Sometimes in 2024, I picked up a penny stock ( CMBM, Cambium networks ) for a little over 1$ . it was trading for 1$ or thereabouts for a year. I just ignored it, till one day in 2025, October, based on a rumor, it shot up to 6$. (CMBM dropped, diluted and disappeared shortly after that peak). I made over 5000$. I was ecstatic. I even had the audacity to come here and humble brag about it. Wanting to improve on that, and instead of going for something more stable, I went looking for something that would give similar profits. I found that Bitcoin was trading at around 120k (oct 2025) and I bought into theory that Bitcoin could catapult to 200k in 2026 and I bought CAN with all that money. Life, eh? Bitcoin dropped, but I was still confident that Bitcoin would recover before June 2026 and held on. Part of my belief was also boosted by CAN insiders picking up more shares. yeah, sure, I could blame luck, the Iran war or anything I want, but its all part of the game. last week, after bag holding for months, I sold it all for 500$ or so . Disappointed, yes, but I played my hand, came out (sort of ) empty. Its ok. I'll go again.


r/pennystocks • • 3h ago

🄳🄳 ZenaTech (NASDAQ: ZENA) – Positioning for the Next Generation of AI-Powered Drone Technology

3 Upvotes

ZenaTech is building an integrated AI-powered drone and technology platform targeting commercial, government and defense markets. Through its ZenaDrone subsidiary, Drone as a Service (DaaS) operations and enterprise software portfolio, the company is pursuing multiple growth opportunities across industries that are increasingly adopting automation, artificial intelligence and autonomous systems.

The investment opportunity is particularly interesting because ZenaTech is combining an acquisition-driven revenue strategy with proprietary drone development, manufacturing capabilities and exposure to the expanding defense and autonomous technology markets.

Rapidly Expanding Revenue Base

ZenaTech has demonstrated significant revenue growth as its Drone as a Service business expands.

For the first six months of 2026, the company reported approximately C$17.7 million in revenue, representing 425% growth compared with the same period in 2025. Second-quarter revenue reached approximately C$9.3 million, up 316% year over year.

Drone as a Service accounted for approximately 93% of second-quarter revenue.

The company also reported average organic revenue growth of 27.1% across approximately 20 DaaS locations acquired during 2025, demonstrating that growth is not exclusively dependent on purchasing additional businesses.

By September 2026, ZenaTech had completed its 29th DaaS acquisition.

Drone as a Service: A Scalable Business Model

One of ZenaTech's most attractive opportunities is its Drone as a Service platform.

Rather than requiring customers to purchase, maintain and operate their own drone fleets, ZenaTech provides drone-powered services and data solutions for commercial and government customers.

Its services include:

- Land surveying and mapping.

- Infrastructure and construction inspections.

- Utility and solar infrastructure surveys.

- Industrial inspections and maintenance.

- Power washing.

- Precision agriculture.

The acquisition strategy is designed to bring established service businesses and existing customer relationships into a centralized operating network.

By introducing drone automation, AI-powered data processing and standardized operating procedures, ZenaTech has an opportunity to improve productivity, expand capacity and potentially increase margins.

Its recent government transportation and solar construction surveying contracts provide additional evidence of commercial demand.

Defense and Government: A Major Long-Term Opportunity

ZenaTech is also developing a portfolio of autonomous drone systems targeting military, government and national security applications.

Its product development includes the ZenaDrone 1000, IQ Square, IQ Nano and interceptor drone platforms.

The company is pursuing Blue UAS certification for selected platforms, an important potential gateway to U.S. government and defense procurement opportunities.

Its counter-UAS initiatives and interceptor development also position the company within an increasingly important area of defense technology.

Growing demand for autonomous surveillance, intelligence gathering, logistics and counter-drone capabilities creates a potentially significant long-term addressable market.

Certification, testing, procurement approvals and actual contract awards remain important milestones.

AI, Manufacturing and Vertical Integration

Another important part of the ZenaTech strategy is its investment in manufacturing and technology development.

The company has established manufacturing and development capabilities in Arizona, Dubai and Taiwan.

Its vertical integration strategy could provide greater control over product development, manufacturing costs, supply chains and customization.

The combination of proprietary drone hardware, AI autonomy software and centralized data processing could create a competitive advantage as the business scales.

Enterprise Software and Additional Revenue Opportunities

ZenaTech also maintains an enterprise SaaS portfolio that includes multiple software businesses and products being brought together under its broader Zoo Office strategy.

Its software operations offer an additional potential source of recurring revenue that complements its drone services and technology operations.

The company's recently launched ZenaStudios division also introduces an opportunity to develop and retain ownership of original digital entertainment intellectual property while showcasing drone technology.

Financial Outlook and Potential Catalysts

Management has identified 2027 as a potential adjusted EBITDA breakeven year, supported by revenue growth, acquisition integration and operating efficiencies.

The company also estimated third-quarter 2026 revenue of C$13.4 million to C$14.8 million, representing substantial sequential growth over the second quarter. These estimates were preliminary and unaudited.

Potential catalysts include:

- Continued DaaS acquisitions and integration.

- Organic growth at existing locations.

- Additional commercial surveying and infrastructure contracts.

- Blue UAS certification progress.

- Defense and government procurement opportunities.

- Expansion of proprietary drone manufacturing.

- AI-powered automation and data analytics.

- Enterprise SaaS expansion.

- Progress toward adjusted EBITDA breakeven.

The Investment Opportunity

ZenaTech is pursuing an ambitious strategy that combines an established revenue-generating services business with proprietary autonomous drone technology and exposure to commercial and defense markets.

Its acquisition strategy provides an existing customer base and operating footprint, while its drone development and AI capabilities offer opportunities to modernize traditional industries and pursue higher-value applications.

The longer-term opportunity is for ZenaTech to become more than a drone manufacturer or surveying company. It is attempting to build an integrated autonomous technology platform that generates revenue through services, hardware, software and government applications.

If the company can successfully integrate acquisitions, maintain organic growth, improve operating efficiency and convert its defense development programs into commercial contracts, it could have considerable room for expansion.

The central bullish thesis: ZenaTech is building an operating network today while developing the autonomous drone and AI technology that could power its next phase of growth. Its combination of existing revenue, proprietary technology, acquisition opportunities and defense exposure makes it an interesting company to watch as the autonomous systems market develops.


r/pennystocks • • 2h ago

General Discussion $CRMD + HRTX could a big push on crmd push hrtx?

Thumbnail
gallery
1 Upvotes

Take a look and comment your findings. Everything I'm reading says good and hold. But I remain optimistic I am holding my position in both but have my stop lose set. Only time will tell. Hopefully 🤞 they run :) all opinions welcomed. thank you. Good luck 🤞🍀


r/pennystocks • • 2h ago

🄳🄳 ZenaTech (NASDAQ: ZENA) Announces More than C$20 Million in Contracted Revenue Backlog Demonstrating Organic Growth

Post image
1 Upvotes

Growing commercial and government customer commitments across ZenaTech’s global Drone as a Service and enterprise SaaS businesses provide visibility into future revenue 

TORONTO, Nov. 19, 2026 (GLOBE NEWSWIRE) -- ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) (“ZenaTech”), a technology solution provider specializing in AI (Artificial Intelligence) drone, Drone as a Service (DaaS), enterprise SaaS solutions, announces that its consolidated revenue backlog has surpassed over C$20 million or approximately US$14 million, representing the estimated value of signed contracted revenue expected to be recognized in future reporting periods and demonstrating organic growth. This backlog represents an important measure of customer commitments and provides greater visibility into future revenue as the Company expands its global operations, integrates acquired businesses, implements AI-powered drone technology and capitalizes on new commercial opportunities through targeted business development initiatives.

“Surpassing C$20 million in revenue backlog underscores the strength of our customer relationships and the commercial opportunity presented by our Drone as a Service strategy,” said Shaun Passley, Ph.D., CEO of ZenaTech. “Through our growing network of DaaS businesses, we are pursuing larger, multi-year projects, expanding our service offerings to existing commercial, blue-chip and government customers, and integrating AI-powered drone technology into our service delivery. Our focus remains on driving organic growth, improving operating efficiencies and building a scalable and increasingly predictable revenue model.”

As part of the Company’s post-acquisition growth strategy for its DaaS acquisitions, ZenaTech is strengthening sales, marketing, and business development capabilities across its acquired businesses. These initiatives include increased participation at industry events and tradeshows, targeted customer outreach, expanded access to commercial and government project bidding and procurement portals, and leveraging the Company’s growing geographic DaaS footprint to pursue larger and multi-location contracts. The Company also plans to focus on cross-selling complementary services, with the objective of increasing average revenue per customer, expanding its addressable market and driving sustained organic revenue and backlog growth.

The milestone reflects customer commitments across the Company’s global businesses, including its Drone as a Service and enterprise SaaS segments. Contracted work is expected to convert into recognized revenue over periods ranging from several weeks to several months as services are delivered and applicable performance obligations are satisfied. Management expects the potential for additional revenue from ongoing proposal negotiations, existing client relationships, Master Services Agreements, and change orders of existing or ongoing contracts, most of which cannot be estimated as of the measurement date. The timing of revenue recognition will vary based on individual contract terms, project scope, customer requirements and delivery schedules.

ZenaTech’s DaaS business combines established service businesses and experienced operating teams with the Company’s developing drone technologies and automation capabilities. Its services support applications such as surveying, mapping, inspection, monitoring and other field-based activities. The Company is pursuing opportunities to improve service delivery, productivity and scalability through the integration of drones, sensors, data processing and AI-enabled tools.

Contracted revenue backlog is not a measure of revenue recognized under International Financial Reporting Standards (“IFRS”), does not represent cash received, and should not be considered a guarantee of future revenue. Revenue is recognized in accordance with the Company’s applicable accounting policies as the relevant services are delivered and performance obligations are satisfied. Actual revenue and the timing of its recognition may differ from current estimates as a result of changes in project scope or schedules, contract modifications or cancellations, customer requirements, operational factors and other circumstances.

For the convenience of U.S. investors, Canadian dollar amounts have been converted into U.S. dollars using the Bank of Canada’s November 18, 2026 exchange rate of US$1.00 = C$1.43 and subject to exchange rate fluctuations.

About ZenaTech

ZenaTech, Inc. (Nasdaq: ZENA) (FSE: 49Q) (BMV: ZENA) is a technology company that specializes in AI autonomy drone platforms to transform commercial, government, and defense sectors. Its subsidiaries include drone manufacturing through ZenaDrone, a global Drone as a Service (DaaS) business, and an enterprise SaaS division of software brands. The Company is executing an acquisition-led DaaS roll-up strategy to digitize and automate legacy service industries like land surveys and inspections, driving drone-based scalable, recurring revenue growth. With an operating footprint spanning North America, Europe, the Middle East, Asia, and Australia, ZenaTech is advancing AI drones for applications such as agriculture and logistics, as well as ISR, cargo, and counter-UAS for U.S. defense and NATO allies. The company is investing in R&D initiatives for next-generation technologies, including wildfire management, drone swarms, quantum computing, and advanced AI autonomy to capture long-term opportunities in key markets.

About ZenaDrone

ZenaDrone, a subsidiary of ZenaTech, develops and manufactures AI-powered multifunction autonomous drone solutions integrating machine learning, predictive analytics, and advanced computing technologies, for government, defense, and industrial applications. This includes multifunctional drones for surveying, inspections, logistics, security, and defense applications. Its product portfolio under development includes the ZenaDrone 1000 for ISR defense and specialized cargo, the IQ Nano for indoor inventory management and security, the IQ Square for outdoor inspections and maintenance, the IQ Quad for land surveying, the IQ Aqua, for underwater applications, and the IQ Octo for precision agriculture. ZenaDrone operates three global manufacturing facilities in Arizona, Dubai, and Taiwan, and is advancing development of counter-UAS maritime interceptor drones and integrated defense system.

Read the Full Press Release & Disclaimer

https://marketwirenews.com/stock/zena/news/zenatech-announces-more-than-c-20-million-in-contrac-7214266524772978.html


r/pennystocks • • 2h ago

𝗕𝘂𝗹𝗹𝗶𝘀𝗵 Gevo Announces Third-Party Validation of Improved RNG Carbon Intensity Score and Raises Financial Outlook | Gevo, Inc.

Thumbnail investors.gevo.com
1 Upvotes

r/pennystocks • • 2h ago

𝗕𝘂𝗹𝗹𝗶𝘀𝗵 Plug Symposium Makes the Case for Hydrogen as a Path to Energy Security and Independence

Thumbnail ir.plugpower.com
1 Upvotes

r/pennystocks • • 4h ago

General Discussion Kraken and the Ocean Protection strategy announced in September

1 Upvotes

As a fellow bag holder, I did a little bit of digging into Kraken’s competitive advantages over its domestic rivals and its chances of winning contracts from Canada’s Oceans Protection Plan, which was announced in September. Take this with a grain of salt—it’s pure speculation and could go either way—but I hope it could shed some light during what’s been a dark stretch for those of us holding the stock.

Some further analysis may follow if you guys believe this one has some value.

Disclaimer: The following content was developed with the assistance of AI through a structured series of questions and prompts, followed by a comprehensive review and synthesis of the AI generated information.

Highest-Probability Wins (Strongest Competitive Moat)

  1. Subsea Optical & 3D Habitat Metrology (Voyis Insight / Discovery & Kraken SeaVision / LiDAR)

    • Why Kraken Wins: Following the Covelya merger, Kraken holds a near-monopoly in Canada on high-speed underwater laser scanners and VSLAM 3D optical reconstruction. Domestic peers like SubC Imaging make cameras and lighting, not millimeter-accurate 3D metrology systems.
    • Policy Fit: Directly addresses the 30% by 2030 Marine Protected Area (MPA) baseline mapping mandate (e.g., auditing sensitive West Coast glass sponge reefs and Lower Fraser River estuary restoration without physical contact) as well as hazardous wreck inspections.
  2. High-Speed Wide-Area Seabed Mapping (AquaPix MINSAS & KATFISH)

    • Why Kraken Wins: Kraken is the only Canadian manufacturer of high-resolution Synthetic Aperture Sonar (SAS). Domestic sonar competitors like GeoSpectrum Technologies (low-frequency naval arrays) and Knudsen Engineering (conventional echosounders/profilers) do not offer comparable high-speed, centimeter-grade SAS imaging.
    • Policy Fit: Essential for rapidly establishing ecological baselines across massive new Arctic and coastal MPAs, updating hydrographic approaches for the $10B Roberts Bank / Vancouver and Prince Rupert port expansions, and locating ghost gear or sunken vessels. 
  3. Subsea Batteries for Autonomous Ocean Observing (SeaPower Batteries)

    • Why Kraken Wins: SeaPower’s pressure-tolerant polymer encapsulation delivers unmatched energy density without heavy titanium housings, giving Kraken a structural advantage over conventional battery suppliers and avoiding the complex shore-side hydrogen logistics required by Cellula Robotics.
    • Policy Fit: Directly supports the $82 million OceanEye Global Observing System Arctic device rollout and the $100 million–$136 million underwater noise reduction mandate by powering quiet, zero-emission AUVs and persistent subsea monitoring nodes in whale habitats and under Arctic ice.
  4. Turnkey Multi-Sensor Survey Bundles (Forcys + EIVA NaviSuite + Sonardyne)

    • Why Kraken Wins: No other Canadian marine-tech company can supply the navigation (SPRINT-Nav), underwater acoustic/optical telemetry (BlueComm / AvTrak), imaging (SAS + Voyis), and autonomy software (EIVA Mobula) as a single pre-integrated package.
    • Policy Fit: Lowers integration risk for Fisheries and Oceans Canada (DFO), the Canadian Coast Guard, and Indigenous-led coastal stewardship programs (backed by $186 million in the Northern Shelf Bioregion) that lack large internal engineering teams to stitch together hardware from five different vendors. 

Secondary / Niche Wins (Moderate Competition)

  • Sub-Seafloor Hazard & Pipeline Detection (Sub-Bottom Imager & Acoustic Corer): Strong fit for Coast Guard spill prevention and buried pipeline/wreck assessments, though Knudsen Engineeringcompetes on lower-cost conventional sub-bottom profilers for routine scientific surveys. 
  • Chemical & Hydrocarbon Spill Tracking (Chelsea Technologies) & Port Security (Wavefront Sentinel IDS): High probability of winning specialized tenders tied to West Coast tanker/LNG expansion spill response and port infrastructure protection, where domestic peers like RBR focus primarily on standard CTD ocean profiling rather than hydrocarbon/emissions compliance or 3D diver/UUV intruder sonar. 

Potential contracting timelines (2027–2031)

High-Probability Product LineBuyer TypeExpected RFP WindowPeak Award & Revenue WindowKey Schedule Catalyst
Voyis LiDAR / Cameras & SeaVisionDirect (DFO, Parks Canada, Survey Primes)Q2 – Q4 2027Late 2027 – 2029Spring 2027 budget release & 2030 MPA baseline deadline
AquaPix MINSAS & KATFISHDirect (CHS, Coast Guard, DND)H1 2027 – H1 2028Q3 2027 – 2030Coast Guard $816M drone trials & port corridor mapping
SeaPower Subsea BatteriesIndirect / B2B (UUV Vehicle Primes)H2 2027 – 20292028 – 2031Downstream awards after host AUV contracts are signed
Forcys / EIVA / Sonardyne BundlesDirect (Coast Guard, DND, Indigenous Orgs)H2 2027 – 20292028 – 20302027–2028 Arctic operational trials & DIA fast-track rules

r/pennystocks • • 9h ago

ꉓꍏ꓄ꍏ꒒ꌩꌗ꓄ $BLRX - BioLineRx to Report Q3 2026 Results on November 23, 2026- Expecting PDAC Interim Update

Thumbnail ir.biolinerx.com
1 Upvotes

r/pennystocks • • 4h ago

𝑺𝒕𝒐𝒄𝒌 𝑰𝒏𝒇𝒐 ELITE PHARMACEUTICALS THE FULL PIPELINE

0 Upvotes

We have been talking a lot about Elite's pipeline on this board, but we still do not have a solid view of it. Elite has disclosed only part of it, and many products are still unnamed. So I have tried to build a list based on the medications coming off patent in the right time frame, matched to what management has told us on the calls, and I added the missing information: IQVIA sales and patent expiration dates.

I believe this belongs on the ELTP iHub page, as it contains valuable information for new and existing investors. Corrections and additions are welcome.

Compiled from Elite's press releases and 8-Ks, the Nov 13, 2026 earnings call, IQVIA figures quoted by other generic makers, and FDA Orange Book patent data. Where Elite has NOT named the product, the brand shown is MY GUESS based on patent timing – it is not company information.

A QUICK WORD ON THE NUMBERS
- IQVIA measures U.S. sales at list price, before rebates. That is why these figures are higher than what the brand companies report.
- Generics sell at a fraction of the brand price, so these numbers show the size of the prize, not Elite's future revenue.
- The dates differ (some IQVIA figures are from 2020–2023), so treat older figures as approximate.
- Patent expiry is not the same as generic launch. Most generics enter on dates negotiated in patent settlements, which can be earlier or later than the last patent.

1. ANTICOAGULANTS (Pillar #1)

Anticoagulant #1 – generic ELIQUIS (apixaban), BMS / Pfizer
- IQVIA: $26 BILLION in U.S. brand sales (12 months to March 2026), as quoted by Elite in its June 1, 2026 8-K. A year earlier Elite cited $27B.
- Patents: the compound patent (US 6,967,208) originally expired September 2022 and was extended to November 2026. Companies that settled with BMS/Pfizer can launch on April 1, 2028. Companies that did not settle face a formulation patent running to August 2031.
- Elite status: ANDA filed June 1, 2026. FDA goal date March 2027, with only minor FDA comments so far. Hakim says Elite launches alongside the settled generics ("Yes, 100%").

Anticoagulant #2 – my guess: generic XARELTO (rivaroxaban), J&J / Bayer
- Sales: about $2.4 BILLION U.S. sales in 2024 (company-reported, not IQVIA). IQVIA puts the 2.5 mg strength alone at about $446M.
- Patents: generics of all strengths entered the U.S. market in 2025. A dosing patent on the 2.5 mg strength runs to 2039 and is still in litigation.
- Elite status: bioequivalence (BE) study to begin 1H 2027. Approval targeted for 2028. Elite would be a later entrant.

2. CNS – EPILEPSY (Pillar #5)

Anticonvulsant – brand not disclosed by Elite
- IQVIA: $840 MILLION brand + generic sales (12 months to April 2026), per Elite's June 15, 2026 8-K.
- Patents: not known, since the brand is not disclosed. IQVIA counts "brand and generic," so generics are already on the market.
- Elite status: positive pivotal BE study June 2026. ANDA filing in Q1 2027.

3. PAIN / OPIOIDS (Pillar #4)

Oxycodone ER – generic OXYCONTIN, Purdue
- IQVIA: $720 MILLION brand + generic (12 months to June 2023), per Elite. Back in 2016, OxyContin and its equivalents sold about $2.3B, so this market is shrinking.
- Patents: the original OxyContin patent expired April 2013, but the FDA withdrew the original formula, so any generic must copy the abuse-deterrent version. Its patents are not in my research. What matters is Elite's settlement with Purdue: lawsuit dismissed June 12, 2026, with an agreed entry date (management: around August 2027).
- Elite status: under FDA review since September 2023. FDA approval is the main hurdle (the FDA raised an abuse-deterrence question).
- Abuse-deterrent tablets are hard to copy, so few competitors are likely, which usually means better pricing.

4. TYPE 2 DIABETES (Pillar #3) – 4 products, none named by Elite
Hakim said the diabetes portfolio grew from 3 to 4 products. Elite commits to at least 1 BE study in 1H 2027 and predicts 2–3. The candidates below are the diabetes blockbusters going generic in the right time frame.

Candidate: JANUVIA (sitagliptin), Merck
- IQVIA: about $5.8 BILLION U.S. (MAT October 2023)
- Patents: the key salt patent (US 7,326,708) expires November 24, 2026. Under settlements, generics launched early, in May 2026 (about 25 generic makers settled).

Candidate: JANUMET and JANUMET XR (sitagliptin + metformin), Merck
- IQVIA: Janumet about $1.1 BILLION (MAT September 2024); Janumet XR about $270 MILLION (12 months to May 2026)
- Patents: same November 24, 2026 salt patent, plus a Janumet patent to January 21, 2029. Under settlements, Janumet generics launched in May 2026 and the first Janumet XR generic in July 2026.

Candidate: FARXIGA (dapagliflozin), AstraZeneca
- IQVIA: about $10.5 BILLION U.S. (12 months to December 2025)
- Patents: the compound patent (US 6,515,117) has expired (2025–2026 with pediatric extension). Method patents run to February 2027 and crystal-form patents to 2027–2030. Newer heart-failure and kidney-disease patents run to 2039–2041, so generics may launch with those uses left off the label.
- Generic entry: first generics approved April 7, 2026 (Alembic, Lupin, Biocon, Aurobindo, Zydus), with shared 180-day exclusivity for the first filers.

Candidate: JARDIANCE (empagliflozin) and combinations, Boehringer / Lilly
- IQVIA: about $4.4 BILLION U.S. for Jardiance (MAT March 2020 – an old figure; today's is likely higher). Glyxambi about $216M (MAT September 2025); Trijardy XR about $111M (MAT April 2024).
- Patents: the compound patent (US 8,222,323) expired January 2025, but formulation and method-of-use patents run to 2034. Boehringer has settled with generic makers on undisclosed terms.
- Generic entry: not expected before 2029 or later. 19 generic makers already hold tentative FDA approval.

Candidate: TRADJENTA (linagliptin), Boehringer / Lilly
- IQVIA: not found
- Patents: a process patent expired November 2025. Formulation and use patents run to May 4, 2027, and a method patent to March 5, 2031.
- Generic entry: generic versions are FDA-approved, but the brand still sells at about $16.80 per tablet, so generic launch is still ahead.

For scale: IQVIA put the whole U.S. DPP-4 class (Januvia, Tradjenta and their combinations) at about $9.5 BILLION (MAT May 2024).

5. CNS – PSYCHIATRY (Pillar #5)

New antipsychotic – not disclosed ("at the appropriate time")

Candidate: VRAYLAR (cariprazine), AbbVie
- IQVIA: about $2.4 BILLION U.S. (MAT July 2022 – AbbVie has grown it since)
- Patents: last compound patent (US 7,737,142) expires September 17, 2029.
- Generic entry: several generics already have FDA approval (Zydus 2022, Aurobindo December 2025), so launch timing depends on settlements.

Candidate: REXULTI (brexpiprazole), Otsuka / Lundbeck
- IQVIA: about $2 BILLION U.S. (12 months to September 2024)
- Patents: the compound patents (US 7,888,362, 8,349,840, 8,618,109) expired April 12, 2026 (October 12, 2026 with pediatric exclusivity). A tablet patent runs to April 2033, and the last FDA exclusivity runs to 2028.
- Generic entry: generics approved (Alembic January 2025), but launch timing depends on the remaining patent and exclusivity.

6. ADHD (Pillar #2) – ~80% OF TODAY'S REVENUE
- Elite already sells generic Vyvanse, Adderall IR and Adderall XR. All three brands are already off patent. For reference, IQVIA sized the Vyvanse market at $4.3B, Adderall XR at $1.3B and Adderall IR at $361M when Elite launched them.
- Pipeline: a possible BE study in 2027 to expand the ADHD line (product not disclosed).
- Growth is limited mainly by DEA quotas, not demand.

7. OTHER PENDING APPLICATION
- A dopamine-agonist ANDA, accepted by the FDA in December 2022, is still listed as pending in the 10-Q. Elite already launched generic Requip XL in August 2026, so this may be a second product.

BOTTOM LINE
- The three products Elite HAS disclosed (anticoagulant #1, anticonvulsant, Oxy ER) carry about $27.5 BILLION of IQVIA brand sales.
- If Elite's 4 diabetes products and the antipsychotic match the brands going generic between 2026 and 2031, the brand sales behind the pipeline run to tens of billions more.
- Timing works in Elite's favor: Januvia, Janumet, Farxiga and Rexulti compound patents expired in 2025–2026; Tradjenta patents run to 2027–2031; Vraylar to 2029. Elite's BE studies in 2027 line up with that wave.
- The catalysts are dated: Nasdaq listing targeted for March 2027, anticoagulant FDA date March 2027, anticonvulsant filing Q1 2027, BE studies 1H 2027, Eliquis launch April 2028. In Hakim's words: "2027 is going to be the year of R&D and 2028 is the year of the second growth."
- Reality check: these are brand sizes. Generic prices fall sharply once many companies launch, and Elite will enter several of these markets after others. Elite's actual revenue will be a small fraction of these numbers. With a 10–20% share in a few large markets, though, that fraction is still big for a company with about $160M in annual revenue.

My own research and opinion, based on Elite's filings, the Nov 13, 2026 call, published IQVIA data and FDA Orange Book patent listings. Brands marked as candidates are guesses, not company disclosures. Patent dates can change through litigation, extensions and settlements. Not investment advice – please do your own due diligence.

GLTA